Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties

Abstract

These results indicate that: (i) teneligliptin ameliorates insulin sensitivity and non-HDL-C levels in subjects with high degrees of insulin resistance. This is not the case with sitagliptin, though similar glycemic efficacies were observed. (ii) glycemic efficacy of teneligliptin may be determined by the balance of its capacity in modulating insulin resistance and beta-cell function depending on the degrees of baseline insulin resistance.

Pancreatic Alpha Cell Dysfunction in Diabetes Mellitus and Its Management Strategies

“…Similarly, DPP-4 inhibitor, sitagliptin and teneligliptin study in type 1 DM patients showed decreased meal stimulated glucagon levels, still unlicensed for type 1 DM and requires large clinical trials to confirm its safety and efficacy for their use in clinical practice. 32 Alpha Cell Dysfunction in Type 2 DM Alpha-cells have a guardian type of role in the islet to maintain the body's capacity to produce insulin 33 and in health the α-and β-cells in the islet regulate each other reciprocally and systemic glucose levels are maintained within narrow range. But, the role of alpha cell in diabetes has been neglected for a long time despite suggested as "bihormonal" disease with an absolute or relative excess of glucagon, which causes higher rate of hepatic glucose production than utilisation favouring hyperglycaemia.…”